Shanghai Junshi Biosciences (688180.SH): Nuo Kao Qi Monoclonal Antibody Injection's New Drug Application Accepted

Stock News12-05

Shanghai Junshi Biosciences Co., Ltd. (688180.SH) announced that it recently received the "Acceptance Notice" issued by the National Medical Products Administration (NMPA). The new drug application for its product, Nuo Kao Qi Monoclonal Antibody Injection (recombinant humanized anti-IL-17A monoclonal antibody injection, product code: JS005), has been accepted for the treatment of moderate to severe plaque psoriasis in adult patients suitable for systemic therapy or phototherapy.

Nuo Kao Qi is a self-developed, highly specific anti-IL-17A monoclonal antibody. IL-17A (interleukin-17A) is a pleiotropic cytokine, and its dysregulated secretion is closely associated with the development of autoimmune diseases such as psoriasis, rheumatoid arthritis, and ankylosing spondylitis. By binding with high affinity to IL-17A and selectively blocking its interaction with the IL-17RA/IL-17RC receptor, Nuo Kao Qi inhibits downstream signaling pathway activation and inflammatory cytokine release, effectively alleviating symptoms of autoimmune diseases.

As of the announcement date, in addition to this new drug application, all participants in the Phase II clinical study of Nuo Kao Qi for the treatment of active ankylosing spondylitis have completed treatment and entered the safety follow-up period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145157960?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 17:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145157960","market":"us","top_or_hot":-1,"title":"Shanghai Junshi Biosciences (688180.SH): Nuo Kao Qi Monoclonal Antibody Injection's New Drug Application Accepted","media":"Stock News","content":"<p>Shanghai Junshi Biosciences Co., Ltd. (688180.SH) announced that it recently received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA). The new drug application for its product, Nuo Kao Qi Monoclonal Antibody Injection (recombinant humanized anti-IL-17A monoclonal antibody injection, product code: JS005), has been accepted for the treatment of moderate to severe plaque psoriasis in adult patients suitable for systemic therapy or phototherapy.</p>\n<p>Nuo Kao Qi is a self-developed, highly specific anti-IL-17A monoclonal antibody. IL-17A (interleukin-17A) is a pleiotropic cytokine, and its dysregulated secretion is closely associated with the development of autoimmune diseases such as psoriasis, rheumatoid arthritis, and ankylosing spondylitis. By binding with high affinity to IL-17A and selectively blocking its interaction with the IL-17RA/IL-17RC receptor, Nuo Kao Qi inhibits downstream signaling pathway activation and inflammatory cytokine release, effectively alleviating symptoms of autoimmune diseases.</p>\n<p>As of the announcement date, in addition to this new drug application, all participants in the Phase II clinical study of Nuo Kao Qi for the treatment of active ankylosing spondylitis have completed treatment and entered the safety follow-up period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Junshi Biosciences (688180.SH): Nuo Kao Qi Monoclonal Antibody Injection's New Drug Application Accepted</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Junshi Biosciences (688180.SH): Nuo Kao Qi Monoclonal Antibody Injection's New Drug Application Accepted\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-05 17:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Junshi Biosciences Co., Ltd. (688180.SH) announced that it recently received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA). The new drug application for its product, Nuo Kao Qi Monoclonal Antibody Injection (recombinant humanized anti-IL-17A monoclonal antibody injection, product code: JS005), has been accepted for the treatment of moderate to severe plaque psoriasis in adult patients suitable for systemic therapy or phototherapy.</p>\n<p>Nuo Kao Qi is a self-developed, highly specific anti-IL-17A monoclonal antibody. IL-17A (interleukin-17A) is a pleiotropic cytokine, and its dysregulated secretion is closely associated with the development of autoimmune diseases such as psoriasis, rheumatoid arthritis, and ankylosing spondylitis. By binding with high affinity to IL-17A and selectively blocking its interaction with the IL-17RA/IL-17RC receptor, Nuo Kao Qi inhibits downstream signaling pathway activation and inflammatory cytokine release, effectively alleviating symptoms of autoimmune diseases.</p>\n<p>As of the announcement date, in addition to this new drug application, all participants in the Phase II clinical study of Nuo Kao Qi for the treatment of active ankylosing spondylitis have completed treatment and entered the safety follow-up period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1145157960","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145157960","pubTimestamp":1764927260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Junshi Biosciences Co., Ltd. (688180.SH) announced that it recently received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA). The new drug application...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688180":"君实生物","BK1583":"高瓴概念","BK0239":"医药制造","BK1515":"抗疫概念","BK1161":"生物科技","01877":"君实生物"},"translate_title":"上海君实生物（688180.SH）：诺考奇单抗注射液新药申请获受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":1,"01877":1},"content_text":"Shanghai Junshi Biosciences Co., Ltd. (688180.SH) announced that it recently received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA). The new drug application for its product, Nuo Kao Qi Monoclonal Antibody Injection (recombinant humanized anti-IL-17A monoclonal antibody injection, product code: JS005), has been accepted for the treatment of moderate to severe plaque psoriasis in adult patients suitable for systemic therapy or phototherapy.\nNuo Kao Qi is a self-developed, highly specific anti-IL-17A monoclonal antibody. IL-17A (interleukin-17A) is a pleiotropic cytokine, and its dysregulated secretion is closely associated with the development of autoimmune diseases such as psoriasis, rheumatoid arthritis, and ankylosing spondylitis. By binding with high affinity to IL-17A and selectively blocking its interaction with the IL-17RA/IL-17RC receptor, Nuo Kao Qi inhibits downstream signaling pathway activation and inflammatory cytokine release, effectively alleviating symptoms of autoimmune diseases.\nAs of the announcement date, in addition to this new drug application, all participants in the Phase II clinical study of Nuo Kao Qi for the treatment of active ankylosing spondylitis have completed treatment and entered the safety follow-up period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145157960","isCrawlerRequest":true}